Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 27;63(4):e01939-18.
doi: 10.1128/AAC.01939-18. Print 2019 Apr.

In Vitro Activity of Tedizolid against Mycobacterium tuberculosis

Pilar Ruiz  1 , Manuel Causse  2 , Manuel Vaquero  1 , Manuel Casal  3
Affiliations

In Vitro Activity of Tedizolid against Mycobacterium tuberculosis

Pilar Ruiz et al. Antimicrob Agents Chemother. .

Abstract

Tedizolid is a novel oxazolidinone with activities against Gram-positive microorganisms, including mycobacteria. We studied the in vitro activity of tedizolid against 120 Mycobacterium tuberculosis strains, including susceptible, first-line-resistant, and multidrug-resistant isolates. MIC was tested using the Bactec 960 MGIT system. MIC90 and MIC50 were 0.5 and 0.25 μg/ml, respectively, in susceptible and resistant strains. Tedizolid may be an alternative in the treatment of resistant M. tuberculosis.

Keywords: Mycobacterium tuberculosis; resistance; tedizolid.

PubMed Disclaimer

References

    1. World Health Organization. 2018. Global tuberculosis report 2018. World Health Organization, Geneva, Switzerland.
    1. Jadhavar PS, Vaja MD, Dhameliya TM, Chakraborti AK. 2015. Oxazolidinones as anti-tubercular agents: discovery, development and future perspectives. Curr Med Chem 22:4379–4397. - PubMed
    1. Kanafani ZA, Corey GR. 2012. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Invest Drugs 21:515–522. doi:10.1517/13543784.2012.660250. - DOI - PubMed
    1. Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, Capitano B, Forrest A, Li J, Nation RL, Bulitta JB. 2014. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother 58:2334–2343. doi:10.1128/AAC.01885-13. - DOI - PMC - PubMed
    1. Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, Ishihara M, Ikeuchi H, Uchino M. 2011. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 17:382–387. doi:10.1007/s10156-010-0182-1. - DOI - PubMed

Publication types

MeSH terms